The kidney and type 2 diabetes mellitus: therapeutic implications of SGLT2 inhibitors

References

• Centers for Disease Control and Prevention. National Diabetes Statistics Report: Estimates of diabetes and its burden in the United States, 2014 [Internet]. Atlanta, GA: U.S. Department of Health and Human Services; 2014. [cited 2016 Jan 8]. Available from: www.cdc.gov/diabetes/pubs/statsreport14/national-diabetes-report-web.pdf.
   Google Scholar
• de Boer IH, Rue TC, Hall YN, et al. Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA. 2011;305(24):2532–2539.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Number of people initiating treatment for end-stage renal disease related to diabetes mellitus (ESRD-DM), United States, 1980–2008 [Internet]; 2014. [ cited 2016 Jan 8]. Available from: www.cdc.gov/diabetes/statistics/esrd/fig1.htm.
   Google Scholar
• Tuttle KR, Bakris GL, Bilous RW, et al. Diabetic kidney disease: a report from an ADA Consensus Conference. Diabetes Care. 2014;37(10):2864–2883.
   PubMed Web of Science ®Google Scholar
• Ritz E, Orth SR. Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med. 1999;341(15):1127–1133.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Incidence of end-stage renal disease related to diabetes mellitus (ESRD-DM) per 100,000 diabetic population, by age, United States, 1980–2008 [Internet]; 2014. [ cited 2016 Jan 8]. Available from: www.cdc.gov/diabetes/statistics/esrd/fig6.htm.
   Google Scholar
• American Diabetes Association. Standards of medical care in diabetes-2014. Diabetes Care. 2014;37(Suppl 1):S14–80.
   PubMed Web of Science ®Google Scholar
• Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35(6):1364–1379.
   PubMed Web of Science ®Google Scholar
• Bailey RA, Wang Y, Zhu V, et al. Chronic kidney disease in US adults with type 2 diabetes: an updated national estimate of prevalence based on Kidney Disease: Improving Global Outcomes (KDIGO) staging. BMC Res Notes. 2014;7:415.
   PubMedGoogle Scholar
• Collins AJ, Li S, Gilbertson DT, et al. Chronic kidney disease and cardiovascular disease in the Medicare population. Kidney Int Suppl. 2003;87:S24–31.
   PubMed Web of Science ®Google Scholar
• Bergman H, Drury DR. The relationship of kidney function to the glucose utilization of the extra abdominal tissues. Am J Physiol. 1938;124(2):279–284.
   Google Scholar
• Bakris GL, Fonseca VA, Sharma K, et al. Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications. Kidney Int. 2009;75(12):1272–1277.
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Davidson JA, Del Prato S. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes Obes Metab. 2012;14(1):5–14.
   PubMed Web of Science ®Google Scholar
• Wilding JP. The role of the kidneys in glucose homeostasis in type 2 diabetes: clinical implications and therapeutic significance through sodium glucose co-transporter 2 inhibitors. Metabolism. 2014;63(10):1228–1237.
   PubMed Web of Science ®Google Scholar
• Stumvoll M, Chintalapudi U, Perriello G, et al. Uptake and release of glucose by the human kidney. Postabsorptive rates and responses to epinephrine. J Clin Invest. 1995;96(5):2528–2533.
   PubMed Web of Science ®Google Scholar
• Cersosimo E, Garlick P, Ferretti J. Regulation of splanchnic and renal substrate supply by insulin in humans. Metabolism. 2000;49(5):676–683.
   PubMed Web of Science ®Google Scholar
• Uldry M, Thorens B. The SLC2 family of facilitated hexose and polyol transporters. Pflugers Arch. 2004;447(5):480–489.
   PubMed Web of Science ®Google Scholar
• Wright EM, Turk E. The sodium/glucose cotransport family SLC5. Pflugers Arch. 2004;447(5):510–518.
   PubMed Web of Science ®Google Scholar
• Bailey CJ. Renal glucose reabsorption inhibitors to treat diabetes. Trends Pharmacol Sci. 2011;32(2):63–71.
   PubMed Web of Science ®Google Scholar
• Wright EM, Hirayama BA, Loo DDF, et al. Intestinal sugar transport. In: Johnson LR, editor. Physiology of the Gastrointestinal Tract. 3rd ed. New York, NY:Raven Press; 1994. p.1751–1772.
   Google Scholar
• Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861–869.
   PubMed Web of Science ®Google Scholar
• Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345(12):851–860.
   PubMed Web of Science ®Google Scholar
• Baba M, Shimbo T, Horio M, et al. Longitudinal study of the decline in renal function in healthy subjects. PLoS One. 2015;10(6):e0129036.
   PubMed Web of Science ®Google Scholar
• Cherney DZ, Perkins BA, Soleymanlou N, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation. 2014;129(5):587–597.
   PubMed Web of Science ®Google Scholar
• Bjornstad P, Cherney DZ, Snell-Bergeon JK, et al. Rapid GFR decline is associated with renal hyperfiltration and impaired GFR in adults with type 1 diabetes. Nephrol Dial Transplant. 2015;30(10):1706–1711.
   PubMed Web of Science ®Google Scholar
• Palatini P. Glomerular hyperfiltration: a marker of early renal damage in pre-diabetes and pre-hypertension. Nephrol Dial Transplant. 2012;27(5):1708–1714.
   PubMed Web of Science ®Google Scholar
• Komala MG, Panchapakesan U, Pollock C, et al. Sodium glucose cotransporter 2 and the diabetic kidney. Curr Opin Nephrol Hypertens. 2013;22(1):113–119.
   PubMed Web of Science ®Google Scholar
• Farber SJ, Berger EY, Earle DP. Effect of diabetes and insulin of the maximum capacity of the renal tubules to reabsorb glucose. J Clin Invest. 1951;30(2):125–129.
   PubMed Web of Science ®Google Scholar
• Mogensen CE. Maximum tubular reabsorption capacity for glucose and renal hemodynamcis during rapid hypertonic glucose infusion in normal and diabetic subjects. Scand J Clin Lab Invest. 1971;28(1):101–109.
   PubMed Web of Science ®Google Scholar
• Rahmoune H, Thompson PW, Ward JM, et al. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes. 2005;54(12):3427–3434.
   PubMed Web of Science ®Google Scholar
• Haneda M, Koya D, Isono M, et al. Overview of glucose signaling in mesangial cells in diabetic nephropathy. J Am Soc Nephrol. 2003;14(5):1374–1382.
   PubMed Web of Science ®Google Scholar
• Loutzenhiser R, Griffin K, Williamson G, et al. Renal autoregulation: new perspectives regarding the protective and regulatory roles of the underlying mechanisms. Am J Physiol Regul Integr Comp Physiol. 2006;290(5):R1153–67.
   PubMed Web of Science ®Google Scholar
• Duran-Salgado MB, Rubio-Guerra AF. Diabetic nephropathy and inflammation. World J Diabetes. 2014;5(3):393–398.
   PubMedGoogle Scholar
• Navarro-González JF, Mora-Fernández C. The role of inflammatory cytokines in diabetic nephropathy. J Am Soc Nephrol. 2008;19(3):433–442.
   PubMed Web of Science ®Google Scholar
• Wada J, Makino H. Inflammation and the pathogenesis of diabetic nephropathy. Clin Sci (Lond). 2013;124(3):139–152.
   PubMed Web of Science ®Google Scholar
• Anderson S, Rennke HG, Brenner BM. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest. 1986;77(6):1993–2000.
   PubMed Web of Science ®Google Scholar
• Farxiga (dapagliflozin). Prescribing Information [Internet]. [cited 2016 Jan 8]. Available from: www1.astrazeneca-us.com/pi/pi_farxiga.pdf.
   Google Scholar
• Invokana (canafliglozin). Prescribing Information [Internet]. [cited 2016 Jan 8]. Available from: www.invokanahcp.com/prescribing-information.pdf.
   Google Scholar
• Jardiance (empagliflozin). Prescribing Information [Internet]. [ cited 2016 Jan 8]. Available from: http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing+Information/PIs/Jardiance/jardiance.pdf.
   Google Scholar
• Kohan DE, Fioretto P, Tang W, et al. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int. 2014;85(4):962–971.
   PubMed Web of Science ®Google Scholar
• Lipska KJ, Bailey CJ, Inzucchi SE. Use of metformin in the setting of mild-to-moderate renal insufficiency. Diabetes Care. 2011;34(6):1431–1437.
   PubMed Web of Science ®Google Scholar
• Giorda CB, Nada E, Tartaglino B. Pharmacokinetics, safety, and efficacy of DPP-4 inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus and renal or hepatic impairment. A systematic review of the literature. Endocrine. 2014;46(3):406–419.
   PubMed Web of Science ®Google Scholar
• Rossetti L, Smith D, Shulman GI, et al. Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest. 1987;79(5):1510–1515.
   PubMed Web of Science ®Google Scholar
• White JR. Jr. Apple trees to sodium glucose co-transporter inhibitors: a review of SGLT2 inhibition. Clin Diabetes. 2010;28(1):5–10.
   Google Scholar
• Sha S, Polidori D, Farrell K, et al. Pharmacodynamic differences between canagliflozin and dapagliflozin: results of a randomized, double-blind, crossover study. Diabetes Obes Metab. 2015;17(2):188–197.
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs. 2015;75(1):33–59.
   PubMed Web of Science ®Google Scholar
• Jahagirdar V, Barnett AH. Empagliflozin for the treatment of type 2 diabetes. Expert Opin Pharmacother. 2014;15(16):2429–2441.
   PubMed Web of Science ®Google Scholar
• Meininger G, Canovachtel W, Polidori D, et al. Canagliflozin for the treatment of adults with type 2 diabetes. Diabetes Management. 2015;5(3):183–201.
   Google Scholar
• Saeed MA, Narendran P. Dapagliflozin for the treatment of type 2 diabetes: a review of the literature. Drug Des Devel Ther. 2014;8:2493–2505.
   PubMed Web of Science ®Google Scholar
• Cefalu WT, Leiter LA, Yoon KH, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet. 2013;382(9896):941–950.
   PubMed Web of Science ®Google Scholar
• Forst T, Guthrie R, Goldenberg R, et al. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone. Diabetes Obes Metab. 2014;16(5):467–477.
   PubMed Web of Science ®Google Scholar
• Filippatos TD, Liberopoulos EN, Elisaf MS. Dapagliflozin in patients with type 2 diabetes mellitus. Ther Adv Endocrinol Metab. 2015;6(1):29–41.
   PubMed Web of Science ®Google Scholar
• Fulcher G, Matthews D, Perkovic V, et al. Canagliflozin (CANA) in subjects with type 2 diabetes mellitus (T2DM) inadequately controlled on sulfonylurea (SU) monotherapy: a CANVAS substudy [abstract 1124-P]. Diabetes. 2013;62(Suppl 1):A292.
   Google Scholar
• Lavalle-González FJ, Januszewicz A, Davidson J, et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia. 2013;56(12):2582–2592.
   PubMed Web of Science ®Google Scholar
• Neal B, Perkovic V, de Zeeuw D, et al. Efficacy and safety of canagliflozin, an inhibitor of sodium glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes. Diabetes Care. 2015;38(3):403–411.
   PubMed Web of Science ®Google Scholar
• Stenlöf K, Cefalu WT, Kim KA, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab. 2013;15(4):372–382.
   PubMed Web of Science ®Google Scholar
• Weir MR, Januszewicz A, Gilbert RE, et al. Effect of canagliflozin on blood pressure and adverse events related to osmotic diuresis and reduced intravascular volume in patients with type 2 diabetes mellitus. J Clin Hypertens (Greenwich). 2014;16(12):875–882.
   PubMed Web of Science ®Google Scholar
• Wilding JP, Charpentier G, Hollander P, et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. Int J Clin Pract. 2013;67(12):1267–1282.
   PubMed Web of Science ®Google Scholar
• Yamout HM, Perkovic V, Davies M, et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy. Am J Nephrol. 2014;40(1):64–74.
   PubMed Web of Science ®Google Scholar
• Ptaszynska A, Johnsson KM, Parikh SJ, et al. Safety profile of dapagliflozin for type 2 diabetes: pooled analysis of clinical studies for overall safety and rare events. Drug Saf. 2014;37(10):815–829.
   PubMed Web of Science ®Google Scholar
• Usiskin K, Kline I, Fung A, et al. Safety and tolerability of canagliflozin in patients with type 2 diabetes: pooled analysis of phase 3 study results. Postgrad Med. 2014;126(3):16–34.
   PubMed Web of Science ®Google Scholar
• Zhang M, Zhang L, Wu B, et al. Dapagliflozin treatment for type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetes Metab Res Rev. 2014;30(3):204–221.
   PubMed Web of Science ®Google Scholar
• Bode B, Stenlöf K, Sullivan D, et al. Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial. Hosp Pract (1995). 2013;41(2):72–84.
   PubMedGoogle Scholar
• Bode B, Stenlöf K, Harris S, et al. Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55–80 years with type 2 diabetes. Diabetes Obes Metab. 2015;17(3):294–303.
   PubMed Web of Science ®Google Scholar
• Leiter LA, Yoon KH, Arias P, et al. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study. Diabetes Care. 2015;38(3):355–364.
   PubMed Web of Science ®Google Scholar
• Nyirjesy P, Sobel JD, Fung A, et al. Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. Curr Med Res Opin. 2014;30(6):1109–1119.
   PubMed Web of Science ®Google Scholar
• Schernthaner G, Gross JL, Rosenstock J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care. 2013;36(9):2508–2515.
   PubMed Web of Science ®Google Scholar
• Stenlöf K, Cefalu WT, Kim KA, et al. Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study. Curr Med Res Opin. 2014;30(2):163–175.
   PubMed Web of Science ®Google Scholar
• Yale JF, Bakris G, Cariou B, et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab. 2013;15(5):463–473.
   PubMed Web of Science ®Google Scholar
• Yale JF, Bakris G, Cariou B, et al. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetes Obes Metab. 2014;16(10):1016–1027.
   PubMed Web of Science ®Google Scholar
• Sinclair A, Bode B, Harris S, et al. Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. BMC Endocr Disord. 2014;14:37.
   PubMed Web of Science ®Google Scholar
• Barnett AH, Mithal A, Manassie J, et al. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2014;2(5):369–384.
   PubMed Web of Science ®Google Scholar
• Hsu CY, Iribarren C, McCulloch CE, et al. Risk factors for end-stage renal disease: 25-year follow-up. Arch Intern Med. 2009;169(4):342–350.
   PubMed Web of Science ®Google Scholar
• De Nicola L, Gabbai FB, Liberti ME, et al. Sodium/glucose cotransporter 2 inhibitors and prevention of diabetic nephropathy: targeting the renal tubule in diabetes. Am J Kidney Dis. 2014;64(1):16–24.
   PubMed Web of Science ®Google Scholar
• Panchapakesan U, Pegg K, Gross S, et al. Effects of SGLT2 inhibition in human kidney proximal tubular cells–renoprotection in diabetic nephropathy? PLoS One. 2013;8(2):e54442.
   PubMed Web of Science ®Google Scholar
• Thomas MC. Renal effects of dapagliflozin in patients with type 2 diabetes. Ther Adv Endocrinol Metab. 2014;5(3):53–61.
   PubMedGoogle Scholar
• Gilbert RE. SGLT-2 inhibition in patients with kidney disease. Diabetes Metab. 2014;40(6 Suppl 1):S23–S27.
   PubMed Web of Science ®Google Scholar
• Gilbert RE. Sodium-glucose linked transporter-2 inhibitors: potential for renoprotection beyond blood glucose lowering? Kidney Int. 2014;86(4):693–700.
   PubMed Web of Science ®Google Scholar
• Vallon V, Gerasimova M, Rose MA, et al. SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice. Am J Physiol Renal Physiol. 2014;306(2):F194–204.
   PubMed Web of Science ®Google Scholar
• Terami N, Ogawa D, Tachibana H, et al. Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice. PLoS One. 2014;9(6):e100777.
   PubMed Web of Science ®Google Scholar
• Gangadharan Komala M, Gross S, Mudaliar H, et al. Inhibition of kidney proximal tubular glucose reabsorption does not prevent against diabetic nephropathy in type 1 diabetes eNOS knockout mice. PLoS One. 2014;9(11):e108994.
   PubMed Web of Science ®Google Scholar
• Perkovic V, Jardine M, Vijapurkar U, et al. Renal effects of canagliflozin in type 2 diabetes mellitus. Curr Med Res Opin. 2015;31(12):2219–2231.
   PubMed Web of Science ®Google Scholar
• Davies MJ, Trujillo A, Vijapurkar U, et al. Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2015;17(4):426–429.
   PubMed Web of Science ®Google Scholar
• Caulfield MJ, Munroe PB, O’Neill D, et al. SLC2A9 is a high-capacity urate transporter in humans. PLoS Med. 2008;5(10):e197.
   PubMed Web of Science ®Google Scholar
• McGill JB. The SGLT2 inhibitor empagliflozin for the treatment of type 2 diabetes mellitus: a bench to bedside review. Diabetes Ther. 2014;5(1):43–63.
   PubMed Web of Science ®Google Scholar
• Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–2128.
   PubMed Web of Science ®Google Scholar
• Holtkamp FA, De Zeeuw D, Thomas MC, et al. An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. Kidney Int. 2011;80(3):282–287.
   PubMed Web of Science ®Google Scholar
• De Zeeuw D, Remuzzi G, Parving HH, et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int. 2004;65(6):2309–2320.
   PubMed Web of Science ®Google Scholar
• Weir MR, Kline I, Xie J, et al. Effect of canagliflozin on serum electrolytes in patients with type 2 diabetes in relation to estimated glomerular filtration rate (eGFR). Curr Med Res Opin. 2014;30(9):1759–1768.
   PubMed Web of Science ®Google Scholar
• Ferrannini E, Berk A, Hantel S, et al. Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes. Diabetes Care. 2013;36(12):4015–4021.
   PubMed Web of Science ®Google Scholar
• Häring HU, Merker L, Seewaldt-Becker E, et al. Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care. 2013;36(11):3396–3404.
   PubMed Web of Science ®Google Scholar
• Heise T, Seman L, Macha S, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple rising doses of empagliflozin in patients with type 2 diabetes. Diabetes Ther. 2013;4(2):331–345.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood, May 2015 [Internet]. [cited 2016 Jan 8]. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm446845.htm.
   Google Scholar
• U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections, December 2015 [Internet]. [ cited 2016 Jan 8]. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm475463.htm.
   Google Scholar
• Erondu N, Desai M, Ways K, et al. Diabetic ketoacidosis and related events in the canagliflozin type 2 diabetes clinical program. Diabetes Care. 2015;38(9):1680–1686.
   PubMed Web of Science ®Google Scholar
• Henry RR, Thakkar P, Tong C, et al. Efficacy and safety of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to insulin in patients with type 1 diabetes. Diabetes Care. 2015;38(12):2258–2265.
   PubMed Web of Science ®Google Scholar
• Peters AL, Buschur EO, Buse JB, et al. Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care. 2015;38(9):1687–1693.
   PubMed Web of Science ®Google Scholar